USPTO serial 99705550
AFFILOCK
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- LIU, PHILIP
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AFFILOCK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Wilmington, DE, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leslye Davidson
Leslye Davidson Davidson Kappel, LLC22nd Floor589 Eighth AvenueNew York, NY 10018Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Antibody reagents used for the detection of antigens in cells and tissue, other than for medical or veterinary purposes; Diagnostic reagents for scientific or research use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; antibodies and antibody-based reagents namely, monoclonal antibodies and full length immunoglobulin molecules for scientific and laboratory research use; Diagnostic reagents and preparations for scientific use, and not for medical or veterinary use | ACTIVE | — |
| 005 | Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs for medical purposes; Antibodies for medical purposes; Antibodies for veterinary purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Antibody reagents used for the detection of antigens in cells and tissue for medical purposes; Immunoassay reagents for medical use; Diagnostic biomarker reagents for medical purposes; Diagnostic test reagents for medical or veterinary purposes; Medical diagnostic reagents and assays for the testing and analysis of body fluids; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Diagnostic reagents for medical purposes for use in identifying, detecting, diagnosing and monitoring infectious diseases, neurodegenerative diseases, oncological diseases, autoimmune diseases, inflammatory disorders, cardiovascular diseases, metabolic disorders, respiratory diseases, gastrointestinal diseases, renal diseases, endocrine disorders, genetic disorders, neurological disorders, toxicological conditions, allergic disorders, reproductive disorders and dermatological disorders; Biological and chemical reagents for medical purposes for use in treating infectious diseases, neurodegenerative diseases, oncological diseases, autoimmune diseases, inflammatory disorders, cardiovascular diseases, metabolic disorders, respiratory diseases, gastrointestinal diseases, renal diseases, endocrine disorders, genetic disorders, neurological disorders, toxicological conditions, allergic disorders, reproductive disorders and dermatological disorders; Diagnostic reagents for medical purposes for use in identifying, detecting, diagnosing and monitoring preventive health and early detection, metabolic health, hormonal balance, gut health and microbiome balance; Biological and chemical reagents for medical purposes for use in treating preventive health and early detection, metabolic health, hormonal balance, gut health and microbiome balance | ACTIVE | — |
| 042 | Research and development services in the field of antibodies; scientific and technological services namely scientific and laboratory testing of materials services for the detection and analysis of biological, chemical, and particulate contaminants in human and animal samples | ACTIVE | — |
| 044 | Antibody testing for medical diagnostic or treatment purposes; Immunochemical medical diagnostic testing services for detecting and measuring antibody levels | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 4, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 14, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 13, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 13, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 13, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 15, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 15, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 15, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 15, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 15, 2026 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jul 15, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 11, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 11, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 11, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 16, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 16, 2026 | NWAP | NEW APPLICATION ENTERED | — |